Compare BioNano Genomics Inc (BNGO) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs VICI Properties Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while VICI Properties Inc trades at $26.29 (market cap $28.94B). The key difference: VICI Properties Inc is far larger — about 2192.4× BioNano Genomics Inc's market cap, and VICI Properties Inc pays a 6.85% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | VICI | |
|---|---|---|
Market Cap | $13.20M | $28.94B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $33.93 |
52-Week Low | $1.09 | $25.94 |
Enterprise Value | $15.81M | $46.16B |
Dividend Yield | — | 6.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
VICI Properties trades at $26.40, up 1.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The REIT shows strong fundamentals with a P/E of 9, net income margin of 76.83%, and consistent cash flow generation. Recent news highlights its 6.8% dividend yield and investment-grade balance sheet, though concerns linger over tenant concentration with Caesars and MGM accounting for 70% of rent.
The outlook remains positive with a consensus price target of $30.75 implying 16.5% upside, supported by 20 buy ratings. Risks include Las Vegas market exposure and potential lease uncertainties from tenant buyouts, but the stock's discounted valuation and secure dividend profile offer a compelling case for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
